Following a disastrous drubbing by the Food and Drug Administration's key advisory committee, the future for Clovis Oncology's (NASDAQ:CLVS) once-promising non-small cell lung cancer drug rociletinib is up in the air. Assuming that the FDA follows the Oncologic Drugs Advisory Committee recommendation and passes on approving rociletinib until it has more late-stage data to parse, then it will leave the door wide open for AstraZeneca plc's (NYSE:AZN) Tagrisso to become a top seller.
